| 2026-06-12 17:25 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Regulatory setback on drug trial; no M&A signals present in filing. |
SEC · detail |
| 2026-05-27 08:50 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Press release on antiviral program for Hantavirus and Ebola; no M&A signals detected. |
SEC · detail |
| 2026-05-26 17:09 |
8-K |
["8.01", "9.01"] |
other |
0.05
|
8-K filing regarding ATM offering agreement and prospectus supplement; no M&A signals. |
SEC · detail |
| 2026-05-15 07:05 |
8-K |
["2.02", "7.01", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings release with no M&A-related disclosures or strategic transaction signals. |
SEC · detail |